Third-line treatment options in metastatic pancreatic cancer patients: a real-world study

por Lu, Hong-Rui, Zhu, Peng-Fei, Deng, Ya-Ya, Chen, Zhe-Ling, Yang, Liu
Publicado 2023

Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review

por Zhu, Peng-Fei, Chen, Yun-Wang, Wang, Ming-Xing, Deng, Ya-Ya, Pan, Shuang-Yue, Chen, Zhe-Ling, Yang, Liu
Publicado 2021

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study

por Deng, Ya-Ya, Zhang, Xin-Yue, Zhu, Peng-Fei, Lu, Hong-Rui, Liu, Qian, Pan, Shuang-Yue, Chen, Zhe-Ling, Yang, Liu
Publicado 2023

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study

por Deng, Ya-Ya, Jiang, Ding-Yi, Zhu, Peng-Fei, Lu, Hongrui, Liu, Qian, Zhang, Xinyue, Pan, Shuang-Yue, Chen, Zhe-Ling, Yang, Liu
Publicado 2023

Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer—a case report and literature review

por Deng, Ya-Ya, Chen, Yun-Wang, Wang, Ming-Xing, Zhu, Peng-Fei, Pan, Shuan-Yue, Jiang, Ding-Yi, Chen, Zhe-Ling, Yang, Liu
Publicado 2023